A novel role for nonactin: interfering with G-quadruplex in RET-driven medullary thyroid cancer.

ABSTRACT:

Background

Medullary Thyroid Carcinoma (MTC) is closely associated with mutations in the RET proto-oncogene, placing the activated RET protein at the center of MTC pathogenesis. Existing therapeutic solutions, primarily tyrosine kinase inhibitors such as selpercatinib, vandetanib, and cabozantinib, have shown moderate efficacy but are accompanied by increased risks of side effects and resistance. This study unveils a promising avenue using nonactin, a compound historically recognized for its antibacterial properties, targeting the G-quadruplex interactions within the RET proto-oncogene.

Method

In this research, high-throughput screening was conducted using a luciferase reporter-based cellular assay. The MTC TT cell line was treated with nonactin for 24 and 48 h. Immunoblotti

SUBMITTER: Alqahtani T 

PROVIDER: S-EPMC11665027 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature